Agilent Technologies and Exelixis sign agreement for customized DNA microarrays
"We are pleased to have Exelixis, a pioneer in the field of comparative genomics, select Agilent's microarrays as research tools to perform high-throughput gene expression profiling analysis," said Bill Buffington, vice president of Agilent's Life Sciences Business Unit. "As a leading provider of customized microarray solutions, consulting services, informatics software and tools for gene expression analysis, Agilent is well placed to help Exelixis identify those key pathways associated with diseases or biologies."
"The Agilent technology provides another tool in our powerful array of integrated genetics and genomics technologies," said Geoffrey Duyk, M.D., Ph.D., chief scientific officer of Exelixis Inc. "We can use the expression profiling analysis in a variety of ways, including our 'Mechanism of Action program,' to study toxicological profiles of drugs, or as a step in validating our proprietary targets in therapeutic areas, such as oncology and inflammation."
Most read news
Topics
Organizations
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.